Korea Research Institute of Bioscience and Biotechnology

Sungkyunkwan University

Lg Life Sciences, Limited

Sungsub Kim

Young Woo Park

Jung Jae Yu

Myeoung Hee Jang

So-Young Choi

Eun-Jung Song

Ji Hyun Park

Joon-Goo Jung

Myung-ho Sohn

Jae Won Jeon

Ji Young Kim

Hye Jin Kim

Jong Sung Koh

Chang-Seok Lee

Hee Han

Min-Jung Kim

Ki Dong Koo

Hyeon Joo Yim

Sung Ho Kim

Mi-ju Park

Je-Ho Lee

Sang Yong Hong

Kyoung-Hee Kim

Young-Soon Jang

Geun Tae Kim

Jae Ryoung Hwang

Seong Cheol Bu

Oh Hwan Kwon

Dong-Jun Yeo

Zi-Ho Yeom

Gwong-Cheung Hur

Dongchul Lim

Hee Oon Han

Mi-Ju Park

The present invention relates to a transmembrane protease, serine (TMPRSS4)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.

TMPRSS4-specific human antibody

The present invention relates to a vascular endothelial growth factor (VEGF)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to VEGF. The VEGF-specific human antibody of the present invention may be used in diagnosis of diseases caused by the VEGF-overexpression, classification of the diseases, visualization, treatment, and prognostic evaluation.

VEGF-specific human antibody

The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.

CD9-specific human antibodies

Novel compounds exhibiting good inhibitory activity versus Dipeptidyl Peptidase-IV(DPP-IV) include those of the following formula (1) or pharmaceutically acceptable salt thereof: wherein A is a substituted or unsubstituted 1,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine, 5,6 -dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine, 4,5-dihydro-7H-isooxazolo[3,4-c]pyridine, 3,4 -dihydroisoquinoline, 5,8-dihydropyrido[3,4-d]pyrimidine, or 6,7 -dihydro[1,3]thiazolo[4,5,c]pyridine, and B is a substituted or unsubstituted piperidin-2-one, morpholin-3-one, oxazolidin-2-one, pyrrolidin-2-one, or 1,5-dihydro-pyrrol-2-one. Methods of preparing the novel inhibitory compounds of formula (1) and pharmaceutical compositions containing the same as an active agent are disclosed.

Dipeptidyl Peptidase-IV inhibiting compounds, method of preparing the same, and pharmaceutical compositions containing the same as an active agent

Growing community of inventors

Daejeon, South Korea

Sungsub Kim